Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 8/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24991032 | 0.93 | C5AR1 (0.51) | MC4RC5AR1 | |
| SCHEMBL23750222 | 0.92 | MC4R (0.45) | MC4RIL23RKISS1RC5AR1 | |
| SCHEMBL18716889 | 0.92 | MC4R (0.53) | MC4RIL23RKISS1RC5AR1 | |
| SCHEMBL29420167 | 0.89 | MC4R (0.64) | MC4RKISS1R | |
| SCHEMBL12057583 | 0.89 | MC4R (0.64) | MC4RKISS1R | |
| SCHEMBL14523926 | 0.89 | MC4R (0.51) | MC4RIL23RKISS1RC5AR1 | |
| SCHEMBL14552580 | 0.88 | MC4R (0.54) | MC4RIL23RKISS1RC5AR1 | |
| SCHEMBL30464981 | 0.86 | IL23R (0.60) | MC4RIL23R | |
| SCHEMBL30464995 | 0.86 | IL23R (0.61) | MC4RIL23RKISS1R | |
| SCHEMBL29814670 | 0.86 | IL23R (0.61) | MC4RIL23RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021158463-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | MC4R 4/4885IL23R 200/4885KISS1R 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.